العلاج المساعد للميلانوما الجلدية المستأصلة بالكامل، المرحلة الباثولوجية IIB–IIC وفق AJCC8، في المرضى من عمر 12 عامًا فأكثر

References

In the KEYNOTE-716 trial, 976 patients (age 12 years) with completely resected AJCC8 pathological stage IIB-IIC melanoma received intravenous pembrolizumab 200 mg (2 mg/kg in paediatric patients) or placebo every 3 weeks (q3w) for 17 cycles or until disease recurrence or unacceptable toxicity.

Adjuvant therapy with either pembrolizumab [ESMO-MCBS v1.1 score: A] or nivolumab [ESMO-MCBS v1.1 score: A] for 12 months should be considered for patients with stage IIB-IIC disease; treatment discussions with the patient should include consideration of the RFS benefit but lack of mature OS data [I, A].

Patients with a negative SLNB can be offered standard follow-up [III, A], clinical trial participation [V, A] or anti-PD-1 therapy for 12 months (stages IIB-IIC) [I, A].